End-to-end Biologics Development Solutions

The acquisition and integration of Cook Pharmica LLC’s business and facility in Bloomington, Indiana, into Catalent’s global biologics network allow its clients to benefit from end-to-end solutions in biologic drug development.

The capabilities of the Bloomington site, which include clinical and commercial biomanufacturing capacity as well as extensive expertise in sterile formulation and fill/finish across liquid and lyophilized vials, prefilled syringes, and cartridges, complement Catalent’s biologics expertise to provide a single, integrated partner supporting a wide range of clinical and commercial needs.

Catalent Biologics’ network includes a state-of-the-art development and biomanufacturing facility in Madison, Wisconsin; fill-finish services in Brussels, Belgium and Limoges, France; SMARTag^® antibody-drug conjugation technology in Emeryville, California; and a network of biologics analytical locations.

Investment and expansion has recently been undertaken at the Madison facility to accommodate two new, 2,000 liter single-use bioreactor systems. This allows the site to support late-phase clinical and commercial production of up to 4,000-liter batches, and analytical and process development laboratories at the site have also been expanded to meet the greater capacity and capabilities.